EX 105
Alternative Names: EX-105Latest Information Update: 29 Jul 2024
At a glance
- Originator Guangzhou Excelmab
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD276 protein inhibitors; CD3 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 31 May 2024 Preclinical trials in Solid tumours in China (Parenteral) before May 2024
- 31 May 2024 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 31 May 2024 Guangzhou ExcelMab plans a first-in-human clinical trial in Solid tumours is due to start